Keros Therapeutics Inc — Liquidità Trimestrale (NASDAQ:KROS) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 615.89 M784.56 M757.16 M742.78 M338.02 M Totale passività 44.33 M55.69 M50.43 M39.2 M34.89 M Patrimonio netto totale 571.55 M728.87 M706.73 M703.58 M303.13 M Totale passività e patrimonio netto 615.89 M784.56 M757.16 M742.78 M338.02 M Debito totale ————— Indebitamento netto —————

Notizie

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Gli EPS di Keros hanno mancato le aspettative per 0,16$, il fatturato appena sotto le previsioni

Keros earnings missed by $0.16, revenue fell short of estimates

Keros Therapeutics nomina l’ex CFO di Lyell nel consiglio

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?